NERV — Minerva Neurosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1598646 ·
Last close
$2.16
Market Cap
$103.13M
52W High
$8.80
52W Low
$1.96
ADV30
178,899
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -9,433,677 | 100,746,561 | 98,278,196 | 20,216,241 | 195,802,092 |
| Jun 2026 | 0 | — | -10,642,159 | 17,466,285 | 95,088,945 | 24,652,086 | 308,389,568 |
| Mar 2026 | 0 | — | -16,671,552 | -125,404,384 | 94,027,156 | 32,659,770 | 348,041,016 |
| Dec 2025 | 0 | — | -4,981,589 | -283,667,663 | 97,968,888 | 82,301,813 | 238,716,970 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-26,168,723
Investing CF
$-50,127,329
Financing CF
$85,700,228
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-28.87
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-796,737,839
Inventory
—
Receivables
—
ST Investments
$50,615,164
EBIT TTM
$-313,725,328
Pretax Income TTM
$-394,349,716
Interest Exp TTM
$0
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -15,102,970 | -293,423,177 | 97,968,888 | 238,716,970 | -140,748,082 | -13,510,936 |
| Dec 2024 | 0 | -21,848,386 | 1,438,865 | 37,143,744 | 62,836,844 | -25,693,100 | -19,550,567 |
| Dec 2023 | 0 | -23,119,576 | -30,005,353 | 56,899,750 | 85,357,240 | -28,457,490 | -14,784,732 |
| Dec 2022 | 0 | -25,231,326 | -32,108,676 | 55,087,233 | 75,111,452 | -20,024,219 | -24,645,143 |
TTM Snapshot
Revenues TTM
$1,852,356
NetIncome TTM
$-394,349,716
OpCashFlow TTM
—
Assets (Latest)
$95,088,945
Forward EPS
$-0.42
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $2.18 · call volume: 3 · put volume: 0
Expected Move to 2026-12-18:
±$1.40
(64.22%) —
implied range
$0.78 –
$3.58
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CATX | Perspective Therapeutics, Inc. | $103.84M | $0.86 | — |
| OGI | ORGANIGRAM GLOBAL INC. | $101.90M | $0.71 | — |
| OKUR | OnKure Therapeutics, Inc. | $104.50M | $2.58 | — |
| UNCY | Unicycive Therapeutics, Inc. | $101.35M | $3.70 | — |
| ORGO | Organogenesis Holdings Inc. | $105.35M | $0.81 | — |
News headlines (Yahoo Finance, 1h cache)
Minerva Neurosciences: Q3 Earnings Snapshot
2026-11-06 14:08 · Yahoo
Minerva Neurosciences Provides Third Quarter 2026 Financial Results and Business Updates
2026-11-06 14:00 · Yahoo
Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London
2026-10-29 11:00 · Yahoo
Minerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of Schizophrenia
2026-10-28 11:00 · Yahoo
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences
2026-08-28 12:00 · Yahoo
Minerva Announces Leadership Transition
2026-04-02 20:05 · Yahoo
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
2026-06-01 20:05 · Yahoo
All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy
2026-05-20 16:00 · Yahoo
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
2026-03-31 20:05 · Yahoo
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
2026-05-05 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.